Lonza Announces Worldwide, Exclusive Licensing and Supply Agreements with California Stem Cell Inc.

June 07,2010 Walkersville, MD, USA

Lonza Inc. (USA) has entered worldwide, exclusive licensing and supply agreements with California Stem Cell Inc. The Lonza - California Stem Cell collaboration makes novel pluripotent stem cell products readily available to researchers worldwide. California Stem Cell’s proprietary methods for scalable production of multiple cell types from human pluripotent stem cells (hPSC), combined with Lonza’s extensive primary cell expertise, specifically enhance screening tools and improve the predictive strength of current cell based models.

“This partnership will address the evolving needs of the research community by making broadly available high purity, human pluripotent stem cell-derived cells and related media products, worldwide,” said Hans Keirstead, Chairman of California Stem Cell’s Scientific Advisory Board. “California Stem Cell’s ability to create innovative tools derived from pluripotent stem cells, combined with Lonza ‘s world-class manufacturing and marketing capabilities, will provide valuable products to accelerate drug discovery and other translational research and development.”

The first products expected to be marketed under this agreement include NeuroPlate™ hPSC-derived Neural Progenitors, and MotorPlate™ hPSC-derived Motor Neuron Progenitors; all accompanied with optimized media. These highly pure and well characterized cells have demonstrated utility in drug discovery, toxicity screening, and neurological research programs. Launch of these products together with associated culture media is expected later in 2010.

In addition to the cell products, Lonza will also begin manufacturing and distributing of California Stem Cell’s media portfolio that includes StemBlast™ Undifferentiated hPSC Culture Medium, EndoBias™ Endodermal Lineage Differentiation Medium and EctoBias™ Ectodermal Lineage Differentiation Medium.

Teun van der Heide, Head of Research Solutions at Lonza, stated “California Stem Cell is one of the few companies that is able to produce cells derived from human pluripotent stem cells in the quantities needed to support our customers’ research programs world wide. Lonza’s portfolio of human primary cell systems is greatly enhanced by this partnership and we look forward to providing these important new products to our customers around the world.”

These products and services complement Lonza’s market leading Clonetics® and Poietics® brands of primary cells and optimized media by providing access to cell types from difficult to source tissues. In addition, these represent Lonza’s first entry into the human pluripotent stem cell market with more in vitro products planned for launch in 2010.

 

About California Stem Cell

California Stem Cell, Inc is a privately held company focused on the manufacturing of high-purity human cells for drug discovery, predictive toxicology and clinical application. Since its founding in 2005, California Stem Cell has developed proprietary methods for the scalable production of human motor neurons, neuronal progenitors, cardiomyocyte progenitors and hepatocytes at its Irvine, California facility. California Stem Cell is currently developing stem cell-derived therapeutic products for the treatment of spinal muscular atrophy, Amyotrophic Lateral Sclerosis and spinal cord injury.

Contact Information:
press@californiastemcell.com
Chris Airriess, 949-725-1750

 

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.69 billion. Further information can be found at www.lonza.com.

 

For further Information:

Lonza Group Ltd:
Media Relations
Dominik Werner
Phone +41 61 316 8798
dominik.werner@lonza.com

Lonza Cologne AG:
Marketing Communication and Product PR
Corinna König-Wildförster
Phone: +49 221 99199 464
pr.cologne@lonza.com

Browse All News
Bg